Lifeline Skin Care was developed by International Stem Cell Corporation (ISCO), a publicly traded biotechnology company which developed a completely new class of human stem cells using a curious natural process called parthenogenesis. Parthenogenetic stem cells are created from unfertilized eggs avoiding the ethical controversies associated with embryonic stem cells.
An additional, and very important benefit: this technology promises to significantly advance the field of regenerative medicine by addressing one of the most common problems in regenerative medicine, that of immune-rejection. ISCO’s research team is focused on using these revolutionary stem cells to treat diseases of the nervous system, including Parkinson’s disease, along with diseases of the liver and the eye. ISCO’s focus is on therapeutic areas where cell therapy has been proven clinically yet practical treatment is limited by the availability of safe immune-matched human cells.
During Vision Research Month, we take time focus our attention on the sight-based research ISCO in which ISCO is involved.
ISCO scientists were among the first scientists in the world to develop methods to create human corneal cells and whole corneal tissue from parthenogenetic stem cells. These cells and tissue can be used to treat many diseases including forms of corneal blindness.
Retinal Based Eye Diseases
ISCO scientists have developed methods to create human retinal epithelium (RPE) cells from parthenogenetic stem cells. These cells can be used to treat many diseases including age-related macular degeneration (AMD). Lifeline Skin Care takes time out during Vision Research Month to remind everyone that we aren’t just another pretty face. Lifeline Skin Care is proud to be a part of a strong research-based organization, helping to fund research through the proceeds generated by the sale of our technically advance skin care products.